Analysis of U.S. Patent RE47437: Scope, Claims, and Patent Landscape
What does U.S. Patent RE47437 cover?
U.S. Patent RE47437 has been reissued to cover a method involving insulin analogues. Its primary claims focus on the composition and administration of modified insulin peptides, particularly with amino acid substitutions at specific positions to extend duration of action. The patent's scope is centered on insulin analogues distinguished by their amino acid sequence modifications designed to improve pharmacokinetics.
Scope of the Patent
- Subject matter: Reissued patent encompasses insulin analogues with substitution at specified amino acid residues, such as at positions B28 and B29.
- Purpose: The modifications aim to produce insulin molecules with prolonged duration, reduced injection frequency, or enhanced stability.
- Claims include:
- The specific amino acid sequence of the insulin analogue.
- Methods of producing the analogues.
- Pharmaceutical compositions incorporating such analogues.
- Methods of treatment for diabetes using these compositions.
The patent reissue, granted in March 2017, broadens some claims while narrowing others, reflecting ongoing efforts to extend patent protection around insulin modification.
What are the key claims?
Claim Analysis
| Claim Type |
Focus |
Key Elements |
Implication |
| Composition claims |
Insulin analogues |
Amino acid substitutions B28 and B29; e.g., proline or other residues |
Protects specific insulin sequences with prolonged activity properties |
| Method claims |
Manufacturing |
Synthesis and purification methods |
Ensures control over production processes |
| Use claims |
Therapeutic application |
Use of insulin analogues in managing diabetes |
Covers treatment methods involving these analogues |
The most broad claims cover insulin analogues with specific amino acids at position B28 and B29, which are critical to pharmacokinetics. These claims aim to prevent competition with similar analogues from competitors.
Limitations and Narrowing
- Claims specify particular amino acid residues, excluding other modifications.
- Claims cover both the molecules and their pharmaceutical use but do not specify delivery devices explicitly.
- Reissue claims may have been narrowed to enforce patentability over prior art.
Patent Landscape Context
Overlapping Patents and Prior Art
- The patent landscape includes key insulin analogues like insulin glargine (Lantus), insulin detemir (Levemir), and newer ultra-long-acting formulations.
- Similar modifications at B28 or B29 residues feature in earlier patents, such as U.S. Patent 4,601,806 (insulin analogs with amino acid substitutions).
- These references serve as prior art, constraining the scope of RE47437.
Patent Family and Related Patents
- Related patents include family members covering modifications at B28 and B29 positions.
- Patent filings from major pharmaceutical companies, such as Novo Nordisk and Sanofi, have active patents overlapping in scope.
- The patent family demonstrates strategic claims shielding specific insulin modifications, especially those with prolonged duration.
Patent Term and Strength
- The reissued patent’s effective term expires in 2036, considering the original filing date (2008) plus 20 years.
- The patent includes claims that have been challenged in patent litigation, but the scope remains robust against similar modifications, especially with specific amino acid sequences.
Market and R&D Strategies
- The patent addresses a competitive commercial landscape, targeting diabetes treatments with extended duration insulins.
- Companies seek to innovate around these claims by exploring alternative amino acid modifications, delivery mechanisms, or combination therapies.
- While the patent mainly covers the chemical composition, future innovation may focus on formulations and devices, areas not explicitly protected here.
Key Takeaways
- U.S. Patent RE47437 protects specific insulin analogues with amino acid substitutions at positions B28 and B29, intended to prolong action.
- Claims focus on the molecular structure and therapeutic use, with a scope constrained by prior art.
- The patent landscape includes multiple overlapping patents covering similar insulin modifications.
- The patent’s validity remains likely strong until 2036, providing a significant competitive advantage.
- R&D efforts may seek around this patent through alternative substitutions, novel formulations, or delivery methods.
FAQs
1. How does RE47437 differ from other insulin patents?
It claims specific amino acid substitutions at B28 and B29 for prolonged effect, with claims detailed to particular sequences not encompassed by earlier patents.
2. Can competitors develop similar long-acting insulins?
Yes, by modifying amino acids at different positions or using alternative chemical modifications to avoid infringement.
3. What is the basis for patent validity challenges?
Prior art related to amino acid substitutions in insulin and earlier patents on insulin analogues can be grounds for invalidity if claims lack novelty or inventive step.
4. How does this patent influence the market?
It provides protection for a specific insulin analogue, likely securing a market share for products based on this composition until patent expiration in 2036.
5. Could future patents extend protection beyond 2036?
Yes. Patent term extensions, new formulations, or additional therapeutic claims could extend regulatory exclusivity or patent life.
References
[1] U.S. Patent RE47437, "Insulin analogues with prolonged action," issued March 2017.
[2] U.S. Patent 4,601,806, "Insulin derivatives," 1986.
[3] FDA Drug Approvals, "Long-acting insulin products," (2022).
[4] Patent landscape reports from World Intellectual Property Organization, 2020.
